Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild-type”

151 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 151 results

Testing effectiveness (Phase 2)UnknownNCT02515734
What this trial is testing

FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Who this might be right for
Colorectal Cancer
Japan Clinical Cancer Research Organization 360
Early research (Phase 1)WithdrawnNCT02573220
What this trial is testing

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer

Who this might be right for
Stage IVA Colorectal CancerStage IVB Colorectal Cancer
University of Chicago
Testing effectiveness (Phase 2)UnknownNCT02071069
What this trial is testing

Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer

Who this might be right for
Incurable Colorectal CancerRAS-wild-type
Tianshu Liu 54
Testing effectiveness (Phase 2)UnknownNCT00964457
What this trial is testing

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Who this might be right for
Rectum Cancer
Copenhagen University Hospital at Herlev 60
Large-scale testing (Phase 3)UnknownNCT04262635
What this trial is testing

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 80
Large-scale testing (Phase 3)Study completedNCT00640471
What this trial is testing

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
NCIC Clinical Trials Group 750
Not applicableUnknownNCT05051592
What this trial is testing

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
National University Hospital, Singapore 40
Large-scale testing (Phase 3)Looking for participantsNCT06280495
What this trial is testing

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Who this might be right for
Colorectal CancerLiver Metastases
Sun Yat-sen University 156
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)Ended earlyNCT05619172
What this trial is testing

Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Who this might be right for
Colorectal Cancer
SOTIO Biotech AG 16
Testing effectiveness (Phase 2)Study completedNCT04513951
What this trial is testing

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 62
Early research (Phase 1)Study completedNCT02510001
What this trial is testing

MEK and MET Inhibition in Colorectal Cancer

Who this might be right for
Solid TumorColorectal Cancer
University of Oxford 82
Testing effectiveness (Phase 2)Ended earlyNCT00845039
What this trial is testing

Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Who this might be right for
Colon CancerRectal Cancer
Eli Lilly and Company 4
Testing effectiveness (Phase 2)Ended earlyNCT01057017
What this trial is testing

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

Who this might be right for
Colorectal Cancer
Brown University 5
Not applicableLooking for participantsNCT04923620
What this trial is testing

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

Who this might be right for
Neoadjuvant TreatmentRectal CancerCetuximab+1 more
Shanghai Minimally Invasive Surgery Center 51
Large-scale testing (Phase 3)Active Not RecruitingNCT03635021
What this trial is testing

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Who this might be right for
Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 419
Large-scale testing (Phase 3)Active Not RecruitingNCT01910610
What this trial is testing

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
GERCOR - Multidisciplinary Oncology Cooperative Group 464
Testing effectiveness (Phase 2)Active Not RecruitingNCT03992456
What this trial is testing

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more
Academic and Community Cancer Research United 12
Large-scale testing (Phase 3)Study completedNCT02934529
What this trial is testing

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Who this might be right for
Metastatic Colorectal Cancer
Ludwig-Maximilians - University of Munich 673
Testing effectiveness (Phase 2)Looking for participantsNCT07257653
What this trial is testing

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsRASBRAF+2 more
Zhejiang University 70
Load More Results